BPC-157 + TB-500 Blend Capsules 1000mcg
Oral research format combining BPC-157 and TB-500. Studied in preclinical protocols where systemic oral absorption of a recovery-peptide blend is the variable of interest. HPLC-tested, third-party COA per batch.
$190.00
Research goals: Recovery & Healing
Description
BPC-157 + TB-500 Blend combines two synthetic peptides commonly studied in tissue-repair and recovery research: BPC-157 (Body Protection Compound-157), a stable gastric pentadecapeptide derived from a human gastric juice fragment, and TB-500 (Ac-LKKTETQ), the N-acetylated 17–23 fragment of thymosin beta-4. The two compounds are paired in this blend because their mechanisms are mechanistically complementary — BPC-157 modulates nitric oxide signaling and growth factor expression to support gastrointestinal, vascular, and connective-tissue healing, while TB-500 sequesters G-actin to drive cell migration, angiogenesis, and post-injury tissue remodeling. Both individual compounds are also available as standalone products in our catalog.
The peer-reviewed evidence summarized below is drawn from studies of each compound separately. Independent published work typically used BPC-157 or Tβ4 alone, in animal models or in clinical trials with full-length Tβ4 (RGN-259/RGN-352).
Important Note on the Evidence Base
To our knowledge, no peer-reviewed clinical or preclinical study has tested the specific BPC-157 + TB-500 combination at the amounts or ratios sold in this product. The rationale for combining them is mechanistic complementarity (different signaling pathways, both implicated in tissue repair) and clinical anecdote in the peptide-therapy community — not formal head-to-head or combination-vs-monotherapy data. Additionally, “TB-500” in commercial products refers specifically to the N-acetylated 17–23 fragment (Ac-LKKTETQ), while the strongest peer-reviewed clinical and preclinical work was conducted on full-length thymosin beta-4 (RGN-259, RGN-352). Whether the heptapeptide fragment fully recapitulates the parent protein’s effects in vivo remains an unresolved question. BPC-157’s evidence base is also concentrated in a single research group (Sikiric and colleagues, University of Zagreb) with limited independent replication. This product is for laboratory research only; neither component is approved by the FDA or EMA.
Published Research on the Component Compounds
BPC-157 Achilles Tendon Healing in Rats — Staresinic et al., Journal of Orthopaedic Research (2003)
This rat-model study tested whether systemic intraperitoneal BPC-157 administration could improve healing of surgically transected Achilles tendons. After complete transection 5 mm proximal to calcaneal insertion, daily BPC-157 (10 μg, 10 ng, or 10 pg per kg body weight) was administered starting 30 minutes post-surgery. All BPC-157 amounts produced histologically and functionally improved tendon healing relative to saline controls, with effects evident across a five-log amount-range. The study established the systemic-administration paradigm that has since been applied across BPC-157’s musculoskeletal research portfolio.1
BPC-157 Medial Collateral Ligament Healing — Cerovecki et al., Journal of Orthopaedic Research (2010)
This follow-up study extended the BPC-157 healing model to surgically transected rat medial collateral ligaments (MCL), evaluating recovery at multiple time points across 90 days post-surgery. The study compared three administration routes — intraperitoneal, oral (in drinking water), and topical (thin cream layer) — all delivered without a carrier. All three routes improved MCL healing, supporting the clinical observation that BPC-157 retains activity orally and topically (a property unusual among peptides), although effect sizes varied by route. Histological and biomechanical recovery were both significantly improved versus controls.2
Thymosin Beta-4 Cardiac Repair — Bock-Marquette et al., Nature (2004)
This foundational paper demonstrated that the G-actin-sequestering peptide Tβ4 promotes myocardial and endothelial cell migration in the embryonic heart and retains this property in postnatal cardiomyocytes. Tβ4 was shown to form a functional complex with PINCH and integrin-linked kinase (ILK), activating the survival kinase Akt. After coronary artery ligation in mice, intraperitoneal Tβ4 treatment upregulated cardiac ILK and Akt activity, enhanced early myocyte survival, and improved cardiac function — establishing the mechanistic basis for the cardiac and broader tissue-repair claims associated with thymosin beta-4 and its 17–23 fragment TB-500.3
RGN-259 Phase 3 Trial in Neurotrophic Keratopathy — Sosne et al., International Journal of Molecular Sciences (2022)
This Phase 3 randomized, placebo-controlled, double-masked clinical trial evaluated topical 0.1% RGN-259 (full-length recombinant Tβ4 ophthalmic solution) in patients with neurotrophic keratopathy. RGN-259 treatment promoted rapid healing of corneal epithelial defects, improved Mackie classification disease stage, and produced significant improvements in ocular discomfort, foreign body sensation, and dryness, with no significant adverse effects. This is the strongest peer-reviewed human evidence in the Tβ4 family, although the formulation tested was full-length Tβ4, not the TB-500 fragment.4
About the Compounds
BPC-157
- Compound class: synthetic stable gastric pentadecapeptide; partial sequence of human Body Protection Compound
- Sequence: H-Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val-OH (GEPPPGKPADDAGLV)
- Synonyms: PL 14736, PLD-116
- CAS Number: 137525-51-0
- Molecular Formula: C62H98N16O22
- Molecular Weight: 1419.55 g/mol
- Mechanism (working): modulation of nitric oxide system, VEGFR-2 expression, and growth factor signaling supporting GI, vascular, and connective-tissue repair
- Regulatory status: not approved by the FDA or EMA
TB-500
- Compound class: synthetic N-acetylated heptapeptide; thymosin beta-4 (17–23) fragment
- Sequence: Ac-Leu-Lys-Lys-Thr-Glu-Thr-Gln (Ac-LKKTETQ); INN: fequesetide (unacetylated form)
- CAS Number: 885340-08-9
- Molecular Formula: C38H68N10O14
- Molecular Weight: 889.02 g/mol
- Mechanism: actin-sequestering motif of Tβ4; modulates cell migration, angiogenesis, and tissue repair signaling
- Regulatory status: not approved by the FDA or EMA. Prohibited by the World Anti-Doping Agency in competition
Product Specifications
- Format: capsules (1:1 BPC-157 to TB-500 ratio per amount)
- Strength: 1000 mcg total peptide per capsule (500 mcg BPC-157 + 500 mcg TB-500)
- Count: 60 capsules per bottle
- Purity: ≥99% (HPLC verified, each component)
- Container: sealed amber bottle
- Certificate of Analysis: lot-specific COA available, with separate purity and identity verification for both component peptides
See the FDA Disclosure, Storage Instructions, and RUO tabs for handling, storage, and regulatory information.
References
- Staresinic M, Sebecic B, Patrlj L, et al. Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth. J Orthop Res. 2003;21(6):976-983. doi:10.1016/S0736-0266(03)00110-4
- Cerovecki T, Bojanic I, Brcic L, et al. Pentadecapeptide BPC 157 (PL 14736) improves ligament healing in the rat. J Orthop Res. 2010;28(9):1155-1161. doi:10.1002/jor.21107
- Bock-Marquette I, Saxena A, White MD, DiMaio JM, Srivastava D. Thymosin β4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair. Nature. 2004;432(7016):466-472. doi:10.1038/nature03000
- Sosne G, Kleinman HK, Springs C, Gross RH, Sung J, Kang S. 0.1% RGN-259 (Thymosin β4) ophthalmic solution promotes healing and improves comfort in neurotrophic keratopathy patients in a randomized, placebo-controlled, double-masked Phase III clinical trial. Int J Mol Sci. 2022;24(1):554. doi:10.3390/ijms24010554
Preparation and storage
Research-only handling information. BPC+TB Blend is sold strictly for in vitro laboratory research. The handling and storage guidance below reflects standard practice in published peptide research literature. BPC+TB Blend is not a drug, supplement, or food product, and is not for human consumption, veterinary use, or medical applications.
Format
- Form: Capsules
- Available strengths: 60ct
- Verified purity: >99% (HPLC, LC–MS)
- Documentation: Batch-specific Certificate of Analysis (COA) included
Handling for Research Use
BPC+TB Blend capsules ship as a pre-encapsulated, dry oral-research format. No reconstitution is required. The capsules can be opened for analytical or assay work that requires the dry powder.
Storage & Handling
- Upon receipt: Store in a cool, dry place away from direct light.
- Short-term storage: Room temperature in a sealed container is acceptable for several months.
- Long-term storage: Refrigeration at 4 °C (39 °F) extends shelf stability. Capsules do not require freezing.
- Humidity: Keep the original desiccant-sealed container closed when not in use. Excess moisture can compromise capsule integrity.
- Light exposure: Minimize exposure to direct light during handling.
Important Notice
All Omnix Peptides products are sold for laboratory, research, or analytical purposes only. They are not for human consumption, veterinary use, or medical applications. Researchers and laboratory professionals must follow all applicable institutional, local, state, and federal regulations governing the handling of research compounds.
Citations
Citations and reference data. Omnix Peptides supplies research-grade compounds for use by qualified laboratory professionals. The references below cite published preclinical research conducted in animal models and in vitro systems. They are not intended to represent clinical evidence in humans, and BPC+TB Blend has not been approved by the FDA, EMA, or any other regulatory authority for any indication.
Compound Reference Data
- Compound: BPC+TB Blend
- CAS Number: 137525-51-0
- Molecular Formula: C62H98N16O22
- Molecular Weight: 1419.55 g/mol
- Sequence: H-Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val-OH (GEPPPGKPADDAGLV)
- Synonyms: —
Selected Published Studies
The following peer-reviewed studies were conducted using animal models or in vitro cell-culture systems. They are listed here as a reference for researchers investigating BPC+TB Blend. None of these studies should be interpreted as recommending BPC+TB Blend for human use, treatment, or any clinical purpose.
- Staresinic M, Sebecic B, Patrlj L, et al. Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth. J Orthop Res. 2003;21(6):976-983. doi:10.1016/S0736-0266(03)00110-4
- Cerovecki T, Bojanic I, Brcic L, et al. Pentadecapeptide BPC 157 (PL 14736) improves ligament healing in the rat. J Orthop Res. 2010;28(9):1155-1161. doi:10.1002/jor.21107
- Bock-Marquette I, Saxena A, White MD, DiMaio JM, Srivastava D. Thymosin β4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair. Nature. 2004;432(7016):466-472. doi:10.1038/nature03000
- Sosne G, Kleinman HK, Springs C, Gross RH, Sung J, Kang S. 0.1% RGN-259 (Thymosin β4) ophthalmic solution promotes healing and improves comfort in neurotrophic keratopathy patients in a randomized, placebo-controlled, double-masked Phase III clinical trial. Int J Mol Sci. 2022;24(1):554. doi:10.3390/ijms24010554
Evidence-Base Disclosure
The published evidence base for BPC+TB Blend consists predominantly of preclinical research — animal models (often rats or mice) and in vitro cell-culture experiments. Where Phase I or Phase II human trials exist, they are noted in the compound page summary. Researchers should interpret the cited literature within the experimental context of each individual study.
Frequently asked questions
Frequently asked questions about the BPC+TB Blend Capsules. Questions on this page cover handling, storage, documentation, and ordering. BPC+TB Blend is sold for laboratory, research, or analytical purposes only — not for human consumption, veterinary use, or medical applications.
Why does Omnix offer BPC+TB Blend in a capsule format?
Capsule format is used in oral-research and analytical contexts where dry, pre-measured administration is preferred over a reconstituted solution. The capsules contain the same research-grade compound supplied in the vial format and are tested to the same purity specification.
Do the BPC+TB Blend capsules require refrigeration?
Capsules are stable at room temperature for several months when kept in a cool, dry place away from direct light. Refrigeration at 4 °C (39 °F) extends shelf stability and is recommended for long-term storage. Capsules do not require freezing.
Can the capsules be opened to access the dry powder?
Yes. The capsule shell can be opened for analytical or assay work that requires direct handling of the dry powder. Once opened, the powder should be used immediately or transferred to a sealed, light-protected container.
Is BPC+TB Blend approved by the FDA?
No. BPC+TB Blend is not approved by the FDA, EMA, or any other regulatory authority for any indication. BPC+TB Blend is sold by Omnix Peptides strictly for laboratory, research, or analytical purposes. It is not for human consumption, veterinary use, or medical applications.
What is included with each BPC+TB Blend Capsules?
Each order includes the sealed product container and a batch-specific Certificate of Analysis (COA) verifying identity and purity by HPLC and LC–MS. The full COA library for Omnix Peptides is available at /coa-lab-reports/.
What is a Certificate of Analysis (COA), and how do I read it?
A COA is a batch-specific lab report that documents the identity, purity, and quality control results for the production lot you receive. The COA lists the compound name, CAS number, lot number, analytical methods used (HPLC, LC–MS), and the measured purity percentage. Every Omnix order includes the COA for the lot shipped.
What is the CAS number for BPC+TB Blend?
The CAS number for BPC+TB Blend is 137525-51-0. Researchers can use this identifier to locate published literature in PubMed and other scientific databases.
How does Omnix Peptides ship orders?
Orders ship from a US-based facility with tracked domestic shipping. Free shipping is offered on orders over $99. Lyophilized vials and capsules ship at ambient temperature; sprays ship insulated when seasonal conditions require it. Tracking information is provided by email after the order ships.
What if my product arrives damaged or the seal is broken?
Contact Omnix Peptides within 48 hours of delivery. Product damaged in transit or arriving with a compromised seal will be replaced at no cost. See the Shipping & Return Policy at /shipping-return-policy/ for full terms.
Where can I find published research on BPC+TB Blend?
Peer-reviewed studies relevant to BPC+TB Blend are listed in the Citations tab on this product page. The same studies can be located independently on PubMed using the CAS number (137525-51-0) or the compound name.
Customer reviews
Certificate of Analysis
Certificate of Analysis (COA) for this batch is available on request. Email orders@omnixpeptides.com with your order number to receive a copy. COAs include HPLC purity analysis performed by an independent third-party laboratory.
Reviews
There are no reviews yet.